30
CARDIOVASCULAR
hamburger
BACK
HONG KONG, INDIA AND SINGAPORE

Proven Therapy Assurance

Key clinical outcomes for Gallant™ ICD solutions include:

98.4% of patients did not receive inappropriate shocks in REDUCE-IT study (CI:97.2-99.2, p<0.0001)1

>800 patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance2

This device is commercially available for use in select international markets.

References

  1. Veltmann C, Wöhrle A, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.
  2. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).

MAT-2010882 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.